Edesa Biotech Inc (EDSA) Stock Price, Quote & News

Company Profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic aller...

Industry: Biotechnology

Sector: Healthcare

Phone: 289 800 9600

Website: www.edesabiotech.com

Address:

100 Spy Court, Markham, Canada

mapleleafdave Jun. 5 at 12:31 AM

$EDSA

0 · Reply

Orion2nite Jun. 4 at 11:43 PM

$EDSA Anyone remember what the old ticker was before they changed name?

1 · Reply

Treb3k Jun. 4 at 8:38 PM

$EDSA well they updated the events page to say when and where the event is. so i think its safe to assume there is nothing coming tonight.

0 · Reply

Treb3k Jun. 4 at 12:22 PM

$EDSA jconde is back baby

1 · Reply

EireTrader Jun. 4 at 12:16 PM

$EDSA .. ERA presentation is during market hours, so its likely we have a PR with presentation data before open tomorrow... Maybe AH today.

2 · Reply

Jhoooon Jun. 4 at 10:54 AM

$EDSA my friends I'm not positioned here for a 20 or 30% jump. Considering the science, upcoming opportunities (canadian health public sector), and current market cap (ridiculous), my target is at the lowest $40 to $50 ($350M-$450M market cap, which would still be very low). Current Share price: $6.9 The more the price is suppressed the more I buy, it's manipulated a lot. We know why. This stock, as well as $BMEA and $MLTX are probably currently the most promising sciences on the nasdaq. NOT AND ADVICE NOT RECOMMANDATION. DO YOUR OWN DUE DILLIGENCE This

0 · Reply

TheDragonsClaw Jun. 3 at 10:40 PM

$EDSA long

0 · Reply

EireTrader Jun. 3 at 7:26 PM

$EDSA ... "Defense research at the NRC" is interesting....

0 · Reply

Boywithathorn Jun. 3 at 7:13 PM

$EDSA get ready shorts. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy

0 · Reply

Boywithathorn Jun. 3 at 6:54 PM

$EDSA $7.09 to $6.50 on like 15k short shares is wild.

0 · Reply

Edesa Biotech Inc trading resumes

2026-05-19T13:35:48.000Z - 16 days ago

Edesa Biotech Inc trading halted, volatility trading pause

May 19, 2026, 9:15 AM EDT - 16 days ago

Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

May 14, 2026, 4:30 PM EDT - 21 days ago

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

2026-04-28T14:26:55.000Z - 5 weeks ago

Edesa Biotech Inc trading halted, volatility trading pause

2026-04-28T14:20:13.000Z - 5 weeks ago

Edesa Biotech Inc trading resumes

Mar 31, 2026, 4:20 PM EDT - 2 months ago

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

2026-03-26T13:37:21.000Z - 2 months ago

Edesa Biotech provides update on EB06 clinical study

Mar 26, 2026, 9:15 AM EDT - 2 months ago

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

2026-02-24T14:20:13.000Z - 3 months ago

Edesa Biotech reports additional results from Phase 3 paridiprubart study

Feb 24, 2026, 9:15 AM EST - 3 months ago

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

2026-02-13T21:25:18.000Z - 3 months ago

Edesa Biotech reports Q1 EPS (28c), consensus (45c)

Feb 13, 2026, 4:20 PM EST - 3 months ago

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Dec 12, 2025, 4:20 PM EST - 6 months ago

Edesa Biotech Reports Fiscal Year 2025 Results

Oct 31, 2025, 4:30 PM EDT - 7 months ago

Edesa Biotech Announces Upcoming Conference Schedule

2025-10-28T11:55:48.000Z - 7 months ago

Edesa Biotech announces Phase 3 study of paridiprubart met primary endpoint

Oct 28, 2025, 7:45 AM EDT - 7 months ago

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Aug 8, 2025, 4:35 PM EDT - 10 months ago

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

2025-07-25T20:50:18.000Z - 11 months ago

Edesa Biotech files $150M mixed securities shelf

2025-06-27T14:35:08.000Z - 1 year ago

Edesa Biotech assumed with a Buy at H.C. Wainwright

2025-05-23T10:55:53.000Z - 1 year ago

Edesa Biotech initiated with a Buy at Lucid Capital

May 14, 2025, 4:15 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

2025-04-04T20:20:09.000Z - 1 year ago

Edesa Biotech says Peter Weiler to succeed Stephen Lemieux as CFO

Apr 4, 2025, 4:15 PM EDT - 1 year ago

Edesa Biotech Announces Chief Financial Officer Transition

2025-03-04T21:36:26.000Z - 1 year ago

Edesa Biotech files to sell 7.81M common shares for holders

Feb 14, 2025, 4:15 PM EST - 1 year ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

2025-02-13T12:55:07.000Z - 1 year ago

Edesa Biotech announces $15M private placement priced at-the-market

Feb 13, 2025, 7:00 AM EST - 1 year ago

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Dec 13, 2024, 4:30 PM EST - 1 year ago

Edesa Biotech Reports Fiscal Year 2024 Results

2024-10-31T12:33:18.000Z - 1 year ago

Edesa Biotech founder Par Nijhawan to invest up to $5M in company

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Edesa Biotech's Founder Makes Strategic Investment in the Company

Sep 13, 2024, 7:38 PM EDT - 1 year ago

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

2024-08-09T20:21:43.000Z - 1 year ago

Edesa Biotech reports Q3 EPS (52c) vs (68c) last year

Aug 9, 2024, 4:20 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

2024-06-24T12:58:43.000Z - 2 years ago

BARDA selects Edesa Biotech drug for U.S. funded platform trial in ARDS

Jun 24, 2024, 8:20 AM EDT - 2 years ago

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

2024-05-10T20:18:59.000Z - 2 years ago

Edesa Biotech reports Q2 EPS (58C), consensus (69C)

May 10, 2024, 4:15 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Apr 2, 2024, 9:00 AM EDT - 2 years ago

Edesa Biotech to Participate in Upcoming Investor Conferences

Mar 21, 2024, 4:30 PM EDT - 2 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Mar 7, 2024, 8:45 AM EST - 2 years ago

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Mar 4, 2024, 4:30 PM EST - 2 years ago

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Feb 9, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Jan 4, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Dec 15, 2023, 4:10 PM EST - 2 years ago

Edesa Biotech Reports Fiscal Year 2023 Results

Nov 20, 2023, 4:05 PM EST - 2 years ago

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 25, 2023, 9:10 AM EDT - 2 years ago

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Oct 12, 2023, 12:15 PM EDT - 2 years ago

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Oct 12, 2023, 12:10 PM EDT - 2 years ago

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech Announces One-for-Seven Reverse Share Split

Sep 28, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Aug 9, 2023, 4:15 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Jul 26, 2023, 9:00 AM EDT - 3 years ago

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Jun 28, 2023, 7:55 AM EDT - 3 years ago

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Jun 27, 2023, 8:15 AM EDT - 3 years ago

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Jun 15, 2023, 8:00 AM EDT - 3 years ago

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

May 11, 2023, 4:30 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

Apr 20, 2023, 8:30 AM EDT - 3 years ago

Edesa Biotech to Participate in Swiss Biotech Day

Apr 4, 2023, 8:45 AM EDT - 3 years ago

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Mar 23, 2023, 4:30 PM EDT - 3 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Mar 15, 2023, 8:10 AM EDT - 3 years ago

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Feb 10, 2023, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Feb 1, 2023, 8:15 AM EST - 3 years ago

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Jan 17, 2023, 8:30 AM EST - 3 years ago

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

Dec 20, 2022, 8:30 AM EST - 3 years ago

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

mapleleafdave Jun. 5 at 12:31 AM

$EDSA

0 · Reply

Orion2nite Jun. 4 at 11:43 PM

$EDSA Anyone remember what the old ticker was before they changed name?

1 · Reply

Treb3k Jun. 4 at 8:38 PM

$EDSA well they updated the events page to say when and where the event is. so i think its safe to assume there is nothing coming tonight.

0 · Reply

Treb3k Jun. 4 at 12:22 PM

$EDSA jconde is back baby

1 · Reply

EireTrader Jun. 4 at 12:16 PM

$EDSA .. ERA presentation is during market hours, so its likely we have a PR with presentation data before open tomorrow... Maybe AH today.

2 · Reply

Jhoooon Jun. 4 at 10:54 AM

0 · Reply

TheDragonsClaw Jun. 3 at 10:40 PM

$EDSA long

0 · Reply

EireTrader Jun. 3 at 7:26 PM

$EDSA ... "Defense research at the NRC" is interesting....

0 · Reply

Boywithathorn Jun. 3 at 7:13 PM

$EDSA get ready shorts. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy

0 · Reply

Boywithathorn Jun. 3 at 6:54 PM

$EDSA $7.09 to $6.50 on like 15k short shares is wild.

0 · Reply

Boywithathorn Jun. 3 at 6:33 PM

$EDSA lmfao. Yep This is the Turdesa we all know.

0 · Reply

Boywithathorn Jun. 3 at 6:17 PM

$EDSA turd-EDSA

0 · Reply

Boywithathorn Jun. 3 at 5:21 PM

$EDSA Boom time coming. Buckle up.

0 · Reply

Jhoooon Jun. 3 at 4:15 PM

$EDSA Remember a couple months ago when Edsa was $ 1.55 ? I announced loudly on several forums (here and on $BMEA, $MLTX, and a few other ones...) that edsa would not long stay that low with a successfull pahse3. A few weeks later it reached up to $20.3 ... X14 in a few weeks. Now it's back to $6.5. I'm loading the truck again. My opinion is we'll go above the previous highs. My target is $ 50-70 Only MY opinion. Due your DD.

1 · Reply

buckshock Jun. 3 at 3:58 PM

$EDSA Cornsilk burnt with potassium could be the next breakthrough for edsa. Research is underway.

0 · Reply

Beowulfdragonslayer Jun. 3 at 3:48 PM

$EDSA companies that engage in multiple reverse splits are usually always scams deductive reasoning 101.

0 · Reply

Beowulfdragonslayer Jun. 3 at 3:46 PM

$EDSA doesnt look good back to 1?

0 · Reply

Jhoooon Jun. 3 at 1:22 PM

$EDSA For that reason, i expect price to be again suppressed as long as the PR is not yet published. I take this opportunity to massively buy. My target is a x10 in a few months ($70)... Meaning a market cap around $650, which is still ridiculous

0 · Reply

Jhoooon Jun. 3 at 12:58 PM

$EDSA $EDSA a big announcement 🥳🥳is coming probably very soon now. The share price could very well beat its yearly highs (in my opinion, and it's just my opinion, we could reach $30 quite easily). Even at $30, that would give a market capitalization of barely $270 million, which is still ridiculous compared to what's happening with this company.

1 · Reply

Treb3k Jun. 3 at 11:42 AM

$EDSA the people have spoken

0 · Reply

RKLBupupup Jun. 3 at 9:30 AM

$EDSA https://archive.fast-edgar.com/20260601/AA22IG2CZ22E2ZZ2222R2ZE3RU8RQZ22X282/

0 · Reply

EdV3 Jun. 2 at 10:21 PM

$EDSA While the subgroup results are encouraging no raw counts or peer review data exists publicly on the full data set. While there are plenty of supportive scientific studies suggesting that blocking tlr4 expression could be a validated target/moa for AKI and similar conditions, what's unknown is how much that particular issue contributes to the overall severity of the patients enrolled in the ITT or impacts mortality; questions also like how would AKI patients w/o ards fare? With no covid? Less severe? if treated with pari I think the sub group analyses warrant merit more on the labeling/ards etiology front; which is somewhat confirmed by the recent zacks report bearish note is that "discussions" and "talks" with the FDA may not yield anything material after all we know their sore spot is regulatory engagement

1 · Reply

Market Cap	64.20M
Revenue (ttm)	0.00
Net Income (ttm)	-7.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	145,300
Avg Vol	703,134
Day's Range	N/A - N/A
Shares Out	8.89M
Stochastic %K	1%
Beta	1.26
Analysts	Strong Sell
Price Target	$11.00